Information Provided By:
Fly News Breaks for December 17, 2019
ADMS
Dec 17, 2019 | 10:58 EDT
Evercore ISI analyst Joshua Schimmer said he is "optimistic this marks the final of many mistakes" from the prior management of Adamas Pharmaceuticals after the company announced results from INROADS, a 3-arm, randomized, double-blind, placebo-controlled study in 594 multiple sclerosis patients with walking impairment. The company's new team can execute on Gocovri with a clean slate and "lightly explore" other pipeline opportunities, contends Schimmer, who has an Outperform rating on Adamas shares. Adamas is down $3.23, or 44%, to $4.07 in morning trading.
News For ADMS From the Last 2 Days
There are no results for your query ADMS